Cardiac rehabilitation decreases plasma pentraxin 3 in patients with cardiovascular diseases

European Journal of Preventive Cardiology

Volumn 19, Issue 6, 2012, Pages 1393-1400

  Fukuda, Taira ^a   Kurano, Miwa ^a   Iida, Haruko ^a   Takano, Haruhito ^a   Tanaka, Tomofumi ^a   Yamamoto, Yumiko ^a   Ikeda, Kenichi ^a   Nagasaki, Mika ^a   Monzen, Koshiro ^a   Uno, Kansei ^a   Kato, Masayoshi ^a   Shiga, Taro ^a   Maemura, Koji ^b   Masuda, Nobuhito ^c   Yamashita, Hiroshi ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a   Nakajima, Toshiaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Perseus Proteomics   (Japan)

Author keywords

Cardiac rehabilitation; high sensitivity C reactive protein; pentraxin 3; serum amyloid A

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTRAXIN 3; SERUM AMYLOID A; TRIACYLGLYCEROL;

ADULT; AEROBIC EXERCISE; ARTICLE; BICYCLE; BICYCLE ERGOMETRY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; FEMALE; HEART MUSCLE OXYGEN CONSUMPTION; HEART REHABILITATION; HUMAN; KINESIOTHERAPY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84873913968     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711422990     Document Type: Article

References (38)

1. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004 ; 116 (10). 682-692
2. Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly medicare beneficiaries. Circulation. 2010 ; 121 (1). 63-70
3. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005 ; 143 (9). 659-672
4. Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the cardiac rehabilitation section of the European association of cardiovascular prevention and rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (1). 1-17
5. Giannuzzi P, Mezzani A, Saner H, Bjornstad H, Fioretti P, Mendes M, et al. Physical activity for primary and secondary prevention. Position paper of the working group on cardiac rehabilitation and exercise physiology of the European society of cardiology. Eur J Cardiovasc Prev Rehabil. 2003 ; 10 (5). 319-327
6. Dod HS, Bhardwaj R, Sajja V, Weidner G, Hobbs GR, Konat GW, et al. Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis. Am J Cardiol. 2010 ; 105 (3). 362-367
7. Williams MA, Ades PA, Hamm LF, Keteyian SJ, LaFontaine TP, Roitman JL, et al. Clinical evidence for a health benefit from cardiac rehabilitation: an update. Am Heart J. 2006 ; 152 (5). 835-841
8. Lavie CJ, Milani RV, Littman AB. Benefits of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol. 1993 ; 22 (3). 678-683
9. Lavie CJ, Milani RV. Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients. Am J Cardiol. 1997 ; 79 (4). 397-401
10. Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol. 2002 ; 39 (4). 653-663
11. Gielen S, Adams V, Mobius-Winkler S, Linke A, Erbs S, Yu J, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol. 2003 ; 42 (5). 861-868
12. Valkeinen H, Aaltonen S, Kujala UM. Effects of exercise training on oxygen uptake in coronary heart disease: a systematic review and meta-analysis. Scand J Med Sci Sports. 2010 ; 20 (4). 545-555
13. Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008 ; 28 (1). 1-13
14. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med. 2007 ; 11 (4). 723-738
15. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005 ; 23 (1). 337-366
16. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004 ; 110 (16). 2349-2354
17. Kunes P, Lonsky V, Mandak J, Kolackova M, Andrys C, Kudlova M, et al. The long pentraxin 3 in cardiac surgery: distinct responses in 'on-pump' and 'off-pump' patients. Scand Cardiovasc J. 2007 ; 41 (3). 171-179
18. Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis. 2008 ; 197 (1). 368-374
19. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011 ; 57 (7). 861-869
20. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008 ; 155 (1). 75-81
21. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol. 2004 ; 43 (6). 1056-1061
22. Nakajima T, Kurano M, Hasegawa T, Takano H, Iida H, Yasuda T, et al. Pentraxin3 and high-sensitive C-reactive protein are independent inflammatory markers released during high-intensity exercise. Eur J Appl Physiol. 2010 ; 110 (5). 905-913
23. Brissette L, Young I, Narindrasorasak S, Kisilevsky R, Deeley R. Differential induction of the serum amyloid A gene family in response to an inflammatory agent and to amyloid-enhancing factor. J Biol Chem. 1989 ; 264 (32). 19327-19332
24. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A. 1994 ; 91 (8). 3186-3190
25. Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, Martin S, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes. Diabetes. 2006 ; 55 (8). 2340-2346
26. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J. 1999 ; 20 (13). 954-959
27. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1- inducible protein, is a novel member of the pentraxin family of acute phase proteins. J Immunol. 1993 ; 150 (5). 1804-1812
28. Brugger-Andersen T, Ponitz V, Kontny F, Staines H, Grundt H, Sagara M, et al. The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain. Thromb Haemost. 2009 ; 102 (3). 555-563
29. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005 ; 98 (4). 1154-1162
30. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers. A systemic review. J Am Coll Cardiol. 2005 ; 45 (10). 1563-1569
31. Plaisance EP, Grandjean PW. Physical activity and high-sesitivity C-reactive protein. Sports Med. 2006 ; 36 (5). 443-458
32. Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP. Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response?. Eur J Vasc Endovasc Surg. 1997 ; 14 (5). 344-350
33. Konig D, Deibert P, Winkler K, Berg A. Association between LDL-cholesterol, statin therapy, physical activity and inflammatory markers in patients with stable coronary heart disease. Exerc Immunol Rev. 2005 ; 11 (1). 97-107
34. Gielen S, Adams V, Linke A, Erbs S, Mobius-Winkler S, Schubert A, et al. Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle. Eur J Cardiovasc Prev Rehabil. 2005 ; 12 (4). 393-400
35. Schumacher A, Peersen K, Sommervoll L, Seljeflot I, Arnesen H, Otterstad JE. Physical performance is associated with markers of vascular inflammation in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2006 ; 13 (3). 356-362
36. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000 ; 102 (25). 3060-3067
37. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005 ; 95 (11A). 3C - 8C
38. Clark DJ, Cleman MW, Pfau SE, Rollins SA, Ramahi TM, Mayer C, et al. Serum complement activation in congestive heart failure. Am Heart J. 2001 ; 141 (4). 684-690